ClinicalTrials.gg

Program

PF-08049820

A development code. Also written as “PF-08049820 MR1”, “PF-08049820 MR2” and “PF-08049820 IR”.

In Pfizer's pipeline, STAT6 inhibitor. Its studies are mostly in Dermatitis, Atopic, led by Pfizer.

Furthest: phase 2, since Oct 9, 20256 company-led studies, 1 open or runningNext primary completion: Feb 2, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer61 open or runningphase 2since Oct 9, 2025Nov 11, 2024Feb 2, 2028phase 2 · NCT07216027
  • Named in Pfizer’s own pipeline as PF-08049820, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06686797 · 71 enrolled · United States
  2. Aug 28, 2025Phase 1 study in Dermatitis, AtopicNCT07172321 · 12 enrolled · United States
  3. Sep 2, 2025Phase 1 study in Dermatitis, AtopicNCT07190430 · 16 enrolled · United States
  4. Oct 9, 2025Phase 2 study in Dermatitis, AtopicNCT07216027 · 165 planned · United States, Bulgaria, Canada and more
  5. Nov 13, 2025Phase 1 study in Dermatitis, AtopicNCT07284173 · 18 enrolled · China
  6. May 12, 2026Phase 1 study in Healthy AdultsNCT07597928 · 24 enrolled · United States

Ahead

  1. Feb 2, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT07216027

TargetBeta

“STAT6 inhibitor”the company's pipeline, read by Claude · source

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07597928Healthy Adults · United States1CompletedAug 7, 202624
NCT07284173Dermatitis, Atopic · China1CompletedDec 18, 202518
NCT07216027Dermatitis, Atopic · United States, Bulgaria, Canada and more2RecruitingFeb 2, 2028165
NCT07190430Dermatitis, Atopic · United States1CompletedDec 15, 202516
NCT07172321Dermatitis, Atopic · United States1CompletedOct 4, 202512
NCT06686797Dermatitis, Atopic · United States1CompletedFeb 23, 202671

How it is read

Names in the registry

  • “PF-08049820”, 5 entries
  • “PF-08049820 MR1”, 1 entry
  • “PF-08049820 MR2”, 1 entry
  • “PF-08049820 IR”, 1 entry

Codes read as this program: PF08049820.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.